Home
TVTX
TVTX News

Latest Travere Therapeutics Inc. (TVTX) News on October 14, 2025

Hims & Hers Leads 15 Growth Stocks Amid Medical Boom

Investor's Business Daily

a month ago

Hims & Hers Leads 15 Growth Stocks Amid Medical Boom

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a month ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Zacks

a month ago

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

Insider Monkey

a month ago

Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Zacks

a month ago

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High

Investor's Business Daily

a month ago

Why Top 4% Stock Travere Therapeutics Skyrocketed To A Three-Year High

Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results

Simply Wall St.

a month ago

Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness

Insider Monkey

4 months ago

Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

Insider Monkey

4 months ago

HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

4 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Business Wire

4 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Business Wire

4 months ago

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Business Wire

4 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

PR Newswire

5 months ago

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

Business Wire

5 months ago

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

GlobeNewswire

5 months ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

5 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Business Wire

5 months ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

Simply Wall St.

5 months ago

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

Travere Therapeutics Reports First Quarter 2025 Financial Results

Business Wire

5 months ago

Travere Therapeutics Reports First Quarter 2025 Financial Results

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Business Wire

6 months ago

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

PR Newswire

6 months ago

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Travere Therapeutics to Report First Quarter 2025 Financial Results

Business Wire

6 months ago

Travere Therapeutics to Report First Quarter 2025 Financial Results

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

6 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank

TipRanks

6 months ago

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Business Wire

6 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

GlobeNewswire

7 months ago

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.

7 months ago

High Growth Tech Stocks In The US With Promising Potential

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

8 months ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics price target raised to $30 from $24 at TD Cowen

TipRanks

8 months ago

Travere Therapeutics price target raised to $30 from $24 at TD Cowen

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

8 months ago

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

8 months ago

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings

GuruFocus.com

8 months ago

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings

Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently

Insider Monkey

8 months ago

Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

8 months ago

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics price target raised to $32 from $27 at Scotiabank

TipRanks

8 months ago

Travere Therapeutics price target raised to $32 from $27 at Scotiabank

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

GlobeNewswire

8 months ago

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Exploring 3 High Growth Tech Stocks in the United States

Simply Wall St.

8 months ago

Exploring 3 High Growth Tech Stocks in the United States

Travere Therapeutics Provides Corporate Update and 2025 Outlook

GlobeNewswire

9 months ago

Travere Therapeutics Provides Corporate Update and 2025 Outlook

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

High Growth Tech Stocks in the United States to Watch

Simply Wall St.

9 months ago

High Growth Tech Stocks in the United States to Watch

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain

Simply Wall St.

10 months ago

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

a year ago

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire

a year ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

a year ago

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...

GuruFocus.com

a year ago

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...

Travere Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics Reports Third Quarter 2024 Financial Results

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

a year ago

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

TipRanks

a year ago

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

GlobeNewswire

a year ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

GlobeNewswire

a year ago

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CNW Group

a year ago

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire

a year ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com

a year ago

Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

Insider Monkey

a year ago

Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

Exploring 3 High Growth Tech Stocks in the United States

Simply Wall St.

a year ago

Exploring 3 High Growth Tech Stocks in the United States

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

GlobeNewswire

a year ago

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire

a year ago

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

GlobeNewswire

a year ago

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

High Growth Tech Stocks To Watch In September 2024

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In September 2024

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

GlobeNewswire

a year ago

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Travere Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Travere Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Travere Therapeutics to Report Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

GlobeNewswire

a year ago

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago

Simply Wall St.

a year ago

Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

ACCESSWIRE

a year ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Intermediate Capital Group plc: Notification of Transactions of Directors

GlobeNewswire

a year ago

Intermediate Capital Group plc: Notification of Transactions of Directors

Lyft stock earns multiple upgrades after investor day

Yahoo Finance Video

a year ago

Lyft stock earns multiple upgrades after investor day

Finally, I can make my iPhone look like total crap

Engadget

a year ago

Finally, I can make my iPhone look like total crap

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

GlobeNewswire

a year ago

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

Stock Split Watch: 3 Growth Stocks That Could Be Next

Motley Fool

a year ago

Stock Split Watch: 3 Growth Stocks That Could Be Next

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

PR Newswire

a year ago

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen

Business Wire

a year ago

Decarbonization of European Refineries: A First Agreement Signed Between TotalEnergies and Air Products for the Delivery of Green Hydrogen

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

GlobeNewswire

a year ago

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

Travere Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term

Simply Wall St.

a year ago

Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term

GuruFocus.com

a year ago

Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...

Travere Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics Reports First Quarter 2024 Financial Results

Travere Therapeutics to Report First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Travere Therapeutics to Report First Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

GlobeNewswire

a year ago

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

PR Newswire

a year ago

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

GlobeNewswire

2 years ago

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

GlobeNewswire

2 years ago

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

GlobeNewswire

2 years ago

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Share on Social Networks: